Grants / Department of Defense / Defense Health Agency Contracting Activity - DHACA

HT9425-23-MRP-MCAA: DoD Melanoma Mid-Career Accelerator Award

Closed Closed September 22, 2023 Opportunity HT9425-23-MRP-MCAA ☆ Save

This grant is closed. A newer notice from the same program is open now: DoW Breast Cancer, Clinical Research Extension Award (HT942526BCRPCREA2). Status: Closes November 18, 2026 (11 days left). It is in our archive of Defense Health Agency Contracting Activity - DHACA notices from 2023.

• Total funding$3.5 million
• Expected awards3
• Cost sharingNot required
• Funding typeCooperative Agreement, Grant

Key dates

Who can apply

This opportunity was open to any type of organization.

• Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses, individuals.

Is this a realistic fit?

• Most of the program's money (59% over five years) went to colleges and universities.
• No cost sharing or match is required.

What the grant funds

The MRP MCAA supports independent, mid-career investigators conducting impactful research in the field of melanoma. The MCAA presents an opportunity for mid-career investigators with prior experience in melanoma research and/or patient care to obtain funding to continue performing impactful research that will also accelerate their career and establish them as leaders in the melanoma field. Preliminary data relevant to melanoma are required. Key aspects of the MCAA: Principal Investigator: The Principal Investigator (PI) must be a mid-career researcher or physician-scientist at the level of Assistant or Associate Professor (or equivalent). The PI must be at least 7 years from obtaining their first faculty-level appointment. Instructors and full professors (or equivalents) are not eligible. The PI must demonstrate previous receipt of at least one peer-reviewed source of extramural funding. The PI’s record of accomplishments (publications, presentations, patents, etc.) and the proposed research will be evaluated regarding the PI’s potential for contributing to the melanoma field. Impact: The impact of the proposed research must relate to at least one of the FY23 MRP Focus Areas in Section II.A.1. Impactful research, including basic research, should expedite the advancement of promising ideas towards clinical utility. The application must articulate the short- and long-term impact the proposed work will have on melanoma research and/or patient care. Continuity Plan: The goal of the MCAA is to support investigators who have laid the foundation for becoming leaders in the melanoma field and who intend to advance the state of the science in melanoma. The Continuity Plan (Attachment 7) should explain how the PI has the potential to establish themselves as a leader in the melanoma field, beyond their own laboratory or institution. Additionally, it should describe the PI’s plan for the continued development of their research program to benefit melanoma research and/or patient care. Synergy with the MRP Melanoma Academy: To enhance networking and collaboration options for both the MCAA PI and MRP Melanoma Academy Scholars, MCAA PIs will be encouraged to participate in Melanoma Academy activities (e.g., networking events, seminars hosted by the MRP Melanoma Academy Leadership) as appropriate.

Category: Science and Technology and other Research and Development.

Applying now

This notice no longer takes applications. Apply under the newer notice, HT942526BCRPCREA2, which is open now.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.